GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan
-
GE HealthCare has completed its acquisition of Sumitomo Chemical’s
50% stake in Nihon Medi-Physics (NMP), giving it full ownership. -
As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in
Japan , is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease - Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will also become President of NMP.

Nihon Medi-Physics headquarters and radiopharmaceutical imaging agents about to go through labelling and packing process.
Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in
NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in
The Company expects this transaction to be neutral to Adjusted EPS2 in year one and accretive thereafter.
GE HealthCare was advised by Solomon Partners Securities, LLC.
The intent to acquire the remaining
Forward-Looking Statements
This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the expected results of the transaction, future market conditions, and the Company’s performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; and the Company may assume unexpected risks and liabilities. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
1 GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024–2028.
2 Non-GAAP financial measure. See our earnings release dated February 13, 2025 for the definition of Adjusted EPS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250330506353/en/
Media contact
David Morris
Executive, Communications, Pharmaceutical Diagnostics
GE HealthCare
+44 7920591370
david.j.morris@gehealthcare.com
Source: GE HealthCare Technologies Inc.